Condition: HIV Infections · AIDS · Virologic Failure · Sponsor: Massachusetts General Hospital
The RESOLVE trial is an open, parallel arm, randomized clinical trial which aims to determine the optimal strategy for management of virologic failure on antiretroviral therapy (ART) with tenofovir, lamivudine, and dolutegravir (TLD) in sub-Saharan Africa. The primary outcome of interest will be viral suppression to \<50 copies/mL at 48 weeks using the FDA snapshot definition. The study will be conducted in Uganda and South Africa.
This description comes directly from the study's public registry record.
Suzanne McCluskey, MD · 617-726-9488 · smccluskey@mgh.harvard.edu
Always discuss trial participation with your own doctor first.
| RK Khan Hospital Clinic | Durban, South Africa | Recruiting |
| Mbarara City Clinic | Mbarara, Uganda | Recruiting |
| Mbarara Regional Referral Hospital Immune Suppression Syndrome Clinic | Mbarara, Uganda | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05373758